TWA
DAWN

TCI Wealth Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

TCI Wealth Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,974
Closed -$26.4K – 709
2023
Q1 		$26.4K Hold
1,974
– – ﹤0.01% 606
2022
Q4 		$42.5K Hold
1,974
– – 0.01% 450
2022
Q3 		$40K Hold
1,974
– – 0.01% 427
2022
Q2 		$35K Buy
+1,974
New +$20.4K 0.01% 462

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

TCI Wealth Advisors's DAWN Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q2 2023, closing a stake of 1,974 shares — an estimated $26.4K sold.

TCI Wealth Advisors first reported a position in DAWN in Q2 2022 and held it in 4 quarters. The position peaked at $42.5K in Q4 2022. 140 funds tracked by Wall St. Rank hold DAWN as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Day One Biopharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 1,974 Day One Biopharmaceuticals shares in Q2 2023, an estimated $26.4K.
  • TCI Wealth Advisors first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 4 quarters.
  • TCI Wealth Advisors's Day One Biopharmaceuticals position peaked at $42.5K in Q4 2022.
  • 140 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.